Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press1410.17650/1994-4098-2014-0-1-69-73GYNECOLOGY. PROBLEMГИНЕКОЛОГИЯ. ПРОБЛЕМАProphylactic adnexectomy in BRCA1 and BRCA2 gene mutation carriers (а review of literature)Профилактическая аднексэктомия у носителей мутации в генах BRCA1 и BRCA2 (обзор литературы)ShendrikovaT. A.ШендриковаТ. А.
Russian Federation
shendrikova.tatyana@gmail.comLaktionovK. P.ЛактионовК. П.
Russian Federation
VasilenkoA. I.ВасиленкоА. И.
Russian Federation
N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва17072014169731707201417072014https://ojrs.abvpress.ru/ojrs/article/view/14

The development of genetics in the study of predisposition to malignancies, to ovarian and breast cancers in particular, as well as the experi- ence of prophylactic surgery to reduce the risks of these diseases have permitted prophylactic bilateral tube ovariectomy to be used as a main technique in BRCA1 and BRCА2 gene mutation carriers. The purpose of this investigation is to demonstrate key studies in this area.

Развитие генетики в области изучения предрасположенности к злокачественным новообразованиям, в частности к развитию рака яичников и рака молочных желез, а также опыт проведения профилактических операций для снижения рисков развития данных заболеваний дали возможность использовать профилактические двусторонние тубовариоэктомии в качестве основного метода у носителей мутации в генах BRCA1 и BRCA2. Целью данной работы является демонстрация ключевых исследований в данном направлении.

BRCA1 and BRCA2 mutationprophylactic tube ovariectomyBRCA1/2-мутацияпрофилактическая тубовариоэктомия1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2010 г. М., 2012. 307 с.Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2010 г. М., 2012. 307 с.2. Портной С.М., Любченко Л.Н., Блохин С.Н. и др. Профилактика BRCA-ассоциированных рака молочной железы и рака яичников. Обзор литературы и собственные данные. Онкогинекология 2012;(1):68–72.Портной С.М., Любченко Л.Н., Блохин С.Н. и др. Профилактика BRCA-ассоциированных рака молочной железы и рака яичников. Обзор литературы и собственные данные. Онкогинекология 2012;(1):68–72.3. Powell C.B., Swisher E.M., Cass I. et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol 2013;129(2):364–71.Powell C.B., Swisher E.M., Cass I. et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol 2013;129(2):364–71.4. National Breast and Ovarian Cancer Centre (NBOCC) (2011) Familial Risk Assessment – Breast and Ovarian Cancer (FRABOC). http://www.nbocc.org.au/fraboc/.National Breast and Ovarian Cancer Centre (NBOCC) (2011) Familial Risk Assessment – Breast and Ovarian Cancer (FRABOC). http://www.nbocc.org.au/fraboc/.5. Manchanda R., Abdelraheim A., Johnson М. et al. Outcome of risk-reducing salpingo- oophorectomy in BRCA carriers and women of unknown mutation status. BJOG 2011;118(7):814–24.Manchanda R., Abdelraheim A., Johnson М. et al. Outcome of risk-reducing salpingo- oophorectomy in BRCA carriers and women of unknown mutation status. BJOG 2011;118(7):814–24.6. Timothy R. Rebbeck, Ph.D., Henry T. et al. Prophylactic оophorectomy in сarriersTimothy R. Rebbeck, Ph.D., Henry T. et al. Prophylactic оophorectomy in сarriersof BRCA1 or BRCA2 mutations. N Engl J Med 2002;346(21):1616–22.7. Finch A.P., Lubinski J., Møller P. et al. Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation. J Clin Oncol 2014 [Epub ahead of print].Finch A.P., Lubinski J., Møller P. et al. Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation. J Clin Oncol 2014 [Epub ahead of print].8. Kauff N.D., Domchek S.M., Friebe T.M. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26(8):1331–7.Kauff N.D., Domchek S.M., Friebe T.M. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26(8):1331–7.9. Dietl J. Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube. Arch Gynecol Obstet 2014;289(2):241–6.Dietl J. Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube. Arch Gynecol Obstet 2014;289(2):241–6.10. Reade C.J., McVey R.M., Tone A.A. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. J Obstet Gynaecol Can 2014;36(2):133–40.Reade C.J., McVey R.M., Tone A.A. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. J Obstet Gynaecol Can 2014;36(2):133–40.11. Tone A.A., Salvador S., Finlayson S.J. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012;10(5):296–306.Tone A.A., Salvador S., Finlayson S.J. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012;10(5):296–306.12. Levanon K., Crum C., Drapkin R. New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact. J Clin Oncol 2008;26(32):5284–93.Levanon K., Crum C., Drapkin R. New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact. J Clin Oncol 2008;26(32):5284–93.13. Mingels M.J., Roelofsen T., van der Laak J.A. et al. Tubal epithelial lesions in salpingooophorectomy specimens of BRCA-mutation carriers and controls. Ginecol Onkol 2012;127(1):88–93.Mingels M.J., Roelofsen T., van der Laak J.A. et al. Tubal epithelial lesions in salpingooophorectomy specimens of BRCA-mutation carriers and controls. Ginecol Onkol 2012;127(1):88–93.14. Любченко Л.Н. Наследственный рак молочной железы и/или яичников: ДНК- диагностика, индивидуальный прогноз, лечение и профилактика. Автореф. дисс. ... д-ра мед. наук. М., 2009. 50 с.Любченко Л.Н. Наследственный рак молочной железы и/или яичников: ДНК- диагностика, индивидуальный прогноз, лечение и профилактика. Автореф. дисс. ... д-ра мед. наук. М., 2009. 50 с.15. Salhab M., Bismohun S., Mokbel K. Risk- reducing strategies for women carrying BRCA1/2 mutations with o focus on prophylactic surgery. BMC WomensSalhab M., Bismohun S., Mokbel K. Risk- reducing strategies for women carrying BRCA1/2 mutations with o focus on prophylactic surgery. BMC WomensHealth 2010;10:28.